Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)

Launched by CHANGHAI HOSPITAL · May 19, 2024

Keywords

ClinConnect Summary

The ADJUPANC trial is studying how effective two different treatments are for patients with pancreatic cancer that has been surgically removed but who are at high risk for the cancer returning. Specifically, the trial compares adjuvant chemoradiotherapy (a combination of chemotherapy and radiation) to chemotherapy alone. The goal is to see which treatment helps patients live longer and have better outcomes after surgery.

To participate in this trial, you need to be between 18 and 75 years old and have a confirmed diagnosis of pancreatic ductal adenocarcinoma, along with certain risk factors like lymph node involvement or specific types of surgery. Participants will undergo regular check-ups and tests to ensure they are healthy enough for the treatments and to monitor their progress. This trial is currently looking for volunteers, and it offers a chance to contribute to important research that could improve treatment options for pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-75 years
• • Pathologically confirmed pancreatic ductal adenocarcinoma
• • Pathologically confirmed lymph node metastasis, R1 or R2 resection or lymphovascular invasion (one of the risk factors)
• • No history of cancer treatment after surgical resection
• • No disease progression confirmed by imaging examinations
• • ECOG 0 to1 point
• • No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10\^9/L, neutrophil count ≥2.0×10\^9, hemoglobin level ≥100g/L, platelet count ≥100×10\^9/L, ALT and AST level \< 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio \<2)
• Exclusion Criteria:
• • History of cancer treatment after surgical resection
• • History of other cancers within 5 years
• • Disease progression, including local pprogression or metastasis, confirmed by imaging examinations
• • ECOG ≥2 points
• • Significant abnormality in blood routine test, liver and kidney function test and coagulation test
• • Active inflammatory bowel disease
• • Gastrointestinal bleeding or perforation within 6 months
• • Infections requiring antibiotics
• • Heart or respirotory insufficiency
• • Pregnant women or breastfeeding women

Trial Officials